# Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

> **NCT00722839** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 68 (actual)

## Conditions studied

- Nonneoplastic Condition

## Interventions

- **BIOLOGICAL:** PADRE-CMV fusion peptide vaccine
- **BIOLOGICAL:** tetanus-CMV fusion peptide vaccine
- **DRUG:** agatolimod sodium

## Key facts

- **NCT ID:** NCT00722839
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2012-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722839, "Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT00722839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*